Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial

被引：0

作者：

Zimmermann, Heiner ^{[1
]}

Koenecke, Christian ^{[2
]}

Dreyling, Martin H. ^{[3
]}

Pott, Christiane ^{[4
]}

Duhrsen, Ulrich ^{[5
]}

Hahn, Dennis ^{[6
]}

Meidenbauer, Norbert ^{[7
]}

Hauser, Ingeborg A. ^{[8
]}

Rummel, Mathias J. ^{[9
]}

Wolf, Dominik ^{[10
,11
]}

Heuser, Michael ^{[2
]}

Schmidt, Christian ^{[12
]}

Schlattmann, Peter ^{[13
]}

Ritgen, Matthias ^{[14
]}

Siebert, Reiner ^{[15
]}

Oschlies, Ilske ^{[16
]}

Anagnostopoulos, Ioannis ^{[17
]}

Trappe, Ralf Ulrich ^{[1
]}

机构：

[1] DIAKO Bremen, Internal Med II Hematol & Oncol, Bremen, Germany

[2] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany

[3] LMU Hosp, Dept Internal Med 3, Munich, Germany

[4] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany

[5] Univ Duisburg Essen, Univ Hosp Essen, Dept Hematol, West German Canc Ctr, Essen, Germany

[6] Katharinen Hosp Stuttgart, Dept Hematol Oncol & Palliat Care, Stuttgart, Germany

[7] Univ Erlangen Nurnberg, Dept Med, Erlangen, Germany

[8] Goethe Univ Frankfurt, Dept Nephrol, UKF, Frankfurt, Germany

[9] Justus Liebig Univ Hosp, Dept Hematol, Clin Haematol & Med Oncol, Giessen, Germany

[10] Univ Hosp Bonn, Dept Hematol Oncol & Rheumatol, Ctr Integrated Oncol Cologne Bonn, Bonn, Germany

[11] Med Univ Innsbruck, Dept Internal Med, Innsbruck, Austria

[12] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany

[13] Jena Univ Hosp, Inst Med Stat, Comp & Data Sci, Jena, Germany

[14] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[15] Ulm Univ & Ulm Univ Med Ctr, Inst Human Genet, Ulm, Germany

[16] Univ Hosp Schleswig Holstein Kiel, Hematopathol Sect, Dept Pathol, Kiel, Germany

[17] Univ Wurzburg, Inst Pathol, Wurzburg, Germany

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146823

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3555

引用

页数：6

共 38 条

[21] Sequential treatment with the anti-CD 20 antibody rituximab and CHOP plus GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): First interim analysis of a multicenter phase II study
Trappe, R
Oertel, S
Choquet, S
LeBlond, V
Papp-Vary, M
Riess, H
BLOOD, 2005, 106 (11) : 274A - 274A
[22] Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients
Trappe, Ralf Ulrich
Dierickx, Daan
Zimmermann, Heiner
Morschhauser, Franck
Mollee, Peter
Zaucha, Jan M.
Dreyling, Martin H.
Duehrsen, Ulrich
Reinke, Petra
Verhoef, Gregor
Subklewe, Marion
Huettmann, Andreas
Tousseyn, Thomas
Salles, Gilles A.
Kliem, Volker
Tarella, Corrado
Van den Neste, Eric W.
Hauser, Ingeborg A.
Gheysens, Olivier
Anagnostopoulos, Iannis
Leblond, Veronique
Riess, Hanno
Choquet, Sylvain
BLOOD, 2015, 126 (23)
[23] Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial
Chaganti, Sridhar
Maycock, Shanna
McIlroy, Graham
Iqbal, Waleed A.
Mason, John
Kanfer, Edward
Kassam, Shireen
Cwynarski, Kate
Wrench, David
Arumainathan, Arvind K.
Fox, Christopher P.
Johnson, Rod
McKay, Pam
Paneesha, Shankara
Rowntree, Clare J.
Balotis, Constantine-George
Collins, Graham P.
Davies, Andrew
Wright, Josh
Wheatley, Keith
Menne, Tobias F.
BLOOD, 2021, 138
[24] Phase II study of sequential reduction in immunosuppression, interferon alpha-2b, and ProMACE-CytaBOM chemotherapy for post-transplant lymphoproliferative disorder (PTLD) (SWOG/ECOG S9239).
Swinnen, LJ
LeBlanc, M
Kasamon, Y
Grogan, T
Gordon, L
Miller, TP
Fisher, RI
BLOOD, 2003, 102 (11) : 403A - 403A
[25] A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Prockop, Susan E.
Hiremath, Minoti
Ye, Wei
Gamelin, Laurence
Navarro, Willis H.
Mahadeo, Kris Michael
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S274 - S274
[26] Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
Trappe, Ralf U.
Dierickx, Daan
Zimmermann, Heiner
Morschhauser, Franck
Mollee, Peter
Zaucha, Jan M.
Dreyling, Martin H.
Duehrsen, Ulrich
Reinke, Petra
Verhoef, Gregor
Subklewe, Marion
Huettmann, Andreas
Tousseyn, Thomas
Salles, Gilles
Kliem, Volker
Hauser, Ingeborg A.
Tarella, Corrado
Van Den Neste, Eric
Gheysens, Olivier
Anagnostopoulos, Ioannis
Leblond, Veronique
Riess, Hanno
Choquet, Sylvain
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (05) : 536 - +
[27] A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV plus PTLD) after Failure of Rituximab or Rituximab and Chemotherapy
Prockop, Susan
Hiremath, Minoti
Ye, Wei
Gamelin, Laurence
Navarro, Willis
Mahadeo, Kris Michael
BLOOD, 2019, 134
[28] Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV plus PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program
Prockop, Susan
Reshef, Ran
Tsai, Donald E.
Bunin, Nancy
Abu-Arja, Rolla
Mahadeo, Kris Michael
Weng, Wen-Kai
Van Besien, Koen
Loeb, David
Nasta, Sunita Dwivedy
Nemecek, Eneida R.
Hiremath, Minoti
Yue, Susan
Sun, Yan
Navarro, Willis
Nikiforow, Sarah
BLOOD, 2019, 134
[29] ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV plus PTLD) after failure of rituximab or rituximab and chemotherapy
Worel, N.
Perez-Simon, J. A.
Barba, P.
Dierickx, D.
Hiremath, M.
Ye, W.
Gamelin, L.
Navarro, W. H.
Choquet, S.
ANNALS OF ONCOLOGY, 2020, 31 : S1426 - S1427
[30] ALLELE STUDY: A MULTICENTER, OPEN LABEL, PHASE 3 STUDY OF TABELECLEUCEL FOR SOLID ORGAN OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT SUBJECTS WITH EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV plus PTLD) AFTER FAILURE OF RITUXIMAB OR RITUXIMAB AND CHEMOTHERAPY
Worel, Nina
Simon Perez, Jose-Antonio
Barba, Pere
Dierickx, Daan
Parmar, Hema
Ye, Wei
Gamelin, Laurence
Navarro, Willis H.
Choquet, Sylvain
TRANSPLANT INTERNATIONAL, 2021, 34 : 25 - 25

← 1 2 3 4 →